Skip to main content

Table 1 Description of treatment groups

From: Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors

 

Treatment group

 

Control

Imatinib

Imatinib

Sunitinib

Regorafenib

Passage

N

Dose

N

Dose

N

Dose

N

Dose

N

Dose

2

2

Untreated

3

50 mg/kg/BID

n/a

n/a

3

40 mg/kg/QD

n/a

n/a

4

6

Untreated

4

50 mg/kg/BID

4

100 mg/kg/BID

n/a

n/a

6

30 mg/kg/QD

  1. N = number of mice; n/a = not available.